High Tumour PD-L1 Is Associated With Poor Outcomes in EGFR-Mutant Lung Cancer Treated With First Generation EGFR TKIs

被引：0

作者：

Liu, J. ^{[1
]}

Itchins, M. ^{[2
]}

Nagrial, A. ^{[3
]}

Cooper, W. ^{[4
]}

De Silva, M. ^{[2
]}

Barnet, M. ^{[5
]}

Varikatt, W. ^{[6
]}

Sivasubramaniam, V. ^{[7
]}

Davis, A. ^{[8
]}

Gill, A. ^{[2
]}

Blinman, P. ^{[9
]}

Lee, K. ^{[9
]}

Hui, R. ^{[1
]}

Gao, B. ^{[1
]}

Pavlakis, N. ^{[2
]}

Clarke, S. ^{[10
]}

Lee, J. ^{[8
]}

Boyer, M. ^{[8
]}

Kao, S. ^{[8
]}

机构：

[1] Crown Princess Mary Canc Ctr, Dept Med Oncol, Westmead, NSW, Australia

[2] Royal North Shore Hosp, Kolling Inst Med Res, Canc Diag & Pathol Grp, St Leonards, NSW, Australia

[3] Blacktown Hosp, Blacktown, NSW, Australia

[4] Royal Prince Alfred Hosp, Tissue Pathol & Diagnost Oncol, Nsw Hlth Pathol, Nsw Pathol, Camperdown, NSW, Australia

[5] Kinghorn Canc Ctr, Med Oncol, Darlinghurst, NSW, Australia

[6] Westmead Hosp, Tissue Pathol & Diagnost Oncol, Inst Clin Pathol & Med Res, Westmead, NSW, Australia

[7] St Vincents Hosp, Sydpath, Darlinghurst, NSW, Australia

[8] Chris OBrien Lifehouse, Dept Med Oncol, Camperdown, NSW, Australia

[9] Concord Repatriat Gen Hosp, Concord, ACT, Australia

[10] Univ Sydney, Sydney, NSW, Australia

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期

关键词：

EGFR; PD-L1; primary resistance;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P76.08

引用

页码：S588 / S589

页数：2

共 50 条

[31] The Opposite Role of PD-L1 Expression in EGFR Mutant Lung Cancer Treated with PD-1 Inhibitor Before and After EGFR TKI: Pilot Study
Park, H. S.
Cho, S. S.
An, H. J.
Yoo, J.
Shim, B. Y.
Kim, S. K.
Cho, D. G.
Kim, S. W.
Ko, J. M.
Park, Y. H.
Kim, C. H.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S466 - S466
[32] PD-L1 Expression and Response to Pembrolizumab in Japanese Patients with EGFR-Mutant Non-small Cell Lung Cancer
Miyawaki, Eriko
Murakami, Haruyasu
Miyawaki, Taichi
Mamesaya, Nobuaki
Kawamura, Takahisa
Kobayashi, Haruki
Nakashima, Kazuhisa
Omori, Shota
Wakuda, Kazushige
Ono, Akira
Kenmotsu, Hirotsugu
Naito, Tateaki
Endo, Masahiro
Takahashi, Toshiaki
ANNALS OF ONCOLOGY, 2019, 30
[33] PD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy
Fan, Y.
Chen, K.
ANNALS OF ONCOLOGY, 2019, 30
[34] PD-L1 Expression in Uncommon EGFR-Mutant Non-Small Cell Lung Cancer and Its Response to Immunotherapy
Chen, K.
Fan, Y.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S747 - S747
[35] Heterogeneity of EGFR-mutant and PD-L1 high-expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor
Kunimasa, Kei
Nakamura, Harumi
Kimura, Madoka
Inoue, Takako
Tamiya, Motohiro
Nishino, Kazumi
Kumagai, Toru
Nakatsuka, Shin-ichi
Imamura, Fumio
ANNALS OF ONCOLOGY, 2018, 29
[36] Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer
Piotrowska, Zofia
Sequist, Lecia V.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (03) : 419 - 421
[37] Acquired Resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-Mutant lung cancer among Hispanics (CLICaP)
Zorrilla, A. Cardona
Arrieta, O.
Rojas, L.
Corrales, L.
Vargas, C.
Carranza, H.
Cuello, M.
Martin, C.
Rosell, R.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S15 - S15
[38] EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients
Karachaliou, Niki
Fernandez-Bruno, Manuel
Paulina Bracht, Jillian Wilhelmina
Rosell, Rafael
TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S23 - S47
[39] Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
Jia, Yijun
Li, Xuefei
Zhao, Chao
Ren, Shengxiang
Su, Chunxia
Gao, Guanghui
Li, Wei
Zhou, Fei
Li, Jiayu
Zhou, Caicun
FRONTIERS IN ONCOLOGY, 2020, 10
[40] Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer
Cho, Jong Ho
Zhou, Wei
Choi, Yoon-La
Sun, Jong-Mu
Choi, Hyejoo
Kim, Tae-Eun
Dolled-Filhart, Marisa
Emancipator, Kenneth
Rutkowski, Mary Anne
Kim, Jhingook
CANCER RESEARCH AND TREATMENT, 2018, 50 (01): : 95 - 102

← 1 2 3 4 5 →